Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Parikh on the Optimal Frontline Therapy for Patients With CLL

April 21st 2017

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses first-line therapy choices for patients with chronic lymphocytic leukemia (CLL).

Dr. Zelenetz on Potential of Acalabrutinib and BGB-3111 in CLL

April 19th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Ibrutinib Discontinuation in CLL Examined to Help Develop Salvage Approaches

April 18th 2017

Patients with chronic lymphocytic leukemia who stopped treatment with ibrutinib (Imbruvica) for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation.

Dr. Goy Discusses Recent Updates in the Treatment of CLL

April 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent updates in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Rai on Handicaps of Chemotherapy in CLL

March 22nd 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the downfalls of chemotherapy in chronic lymphocytic leukemia (CLL).

New Standards Are Emerging for Follicular Lymphoma and CLL

March 20th 2017

Controlling indolent non-Hodgkin lymphoma remains a priority as it has the potential to transform to aggressive or high-grade lymphoma.

Dr. Brown on the Development of Treatments for CLL

March 9th 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the development of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) in the next 5 to 10 years.

Ublituximab/Ibrutinib Combo Succeeds in Phase III CLL Study

March 7th 2017

The addition of ublituximab to ibrutinib significantly improved objective response rates compared with ibrutinib alone for patients with previously treated high-risk chronic lymphocytic leukemia.

Dr. Brown on PI3 Kinase Inhibitors in CLL

March 2nd 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

Expert Discusses Emerging Agents in CLL

March 2nd 2017

Jennifer Brown, MD, PhD, discusses novel agents and the future treatment landscape of chronic lymphocytic leukemia.

Dr. Rai on Novel Approaches in CLL

February 28th 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses some novel approaches being used in the field of chronic lymphocytic leukemia.

Dr. Brown Discusses Acalabrutinib in CLL

February 28th 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL

February 25th 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL

February 24th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Dr. Jones on Studying Venetoclax in R/R CLL

February 24th 2017

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Dr. Jones on the Safety of Venetoclax in CLL

February 23rd 2017

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

February 22nd 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Dr. Woyach on Phase II Trial of MOR208 Trial in CLL

February 18th 2017

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

February 10th 2017

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL

February 10th 2017

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.